VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine
Vaccine Information
  • Vaccine Name: Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Type: DNA vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: None
  • Antigen: macrophage inflammatory protein 3 alpha (NCT01209871)
  • Immunization Route: Intradermal injection (i.d.)
  • Description: Patients with Asymptomatic Phase Lymphoplasmacytic Lymphoma receive autologous lymphoma immunoglobulin-derived single-chain variable fragment (scFV)-chemokine DNA vaccine intradermally. The DNA vaccine encodes macrophage inflammatory protein 3 alpha (MIP3a)-fused lymphoma idiotype in single chain format. (NCT01209871)
Host Response
References
NCT01209871: Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma [https://clinicaltrials.gov/study/NCT01209871]